The Lived Experience of Patients With Chronic Kidney Disease: Insights From DISCOVER CKD

Findings from this multinational qualitative study suggest that patients may experience symptoms and signs of disease prior to diagnosis; however, these are often nonspecific and may not be directly associated with CKD. Once diagnosed, the burden of CKD can have a diverse, negative impact on various aspects of patients' lives. This highlights the need for early identification of at-risk individuals, and the importance of early CKD diagnosis and management with guideline-directed therapies to either prevent further deterioration of CKD or slow its progression, thus reducing symptom burden and improving quality of life.

Authors

Institutions

Publication Details

Journal
American Journal of Nephrology
Published
2024-08-22
DOI
https://doi.org/10.1159/000541064
Citations
2
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
0.68
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Lived Experience of Patients With Chronic Kidney Disease: Insights From DISCOVER CKD

Eiichiro Kanda, Naoki Kashihara, Steven Fishbane, Carol A. Pollock et al.
2 citations
American Journal of Nephrology
Dialysis and Renal Disease Management
0.68
article

The Lived Experience of Patients With Chronic Kidney Disease: Insights From DISCOVER CKD

Eiichiro Kanda, Naoki Kashihara, Steven Fishbane, Carol A. Pollock, Juan José García Sánchez, Roberto Pecoits‐Filho, Andrew Linder, Anna Niklasson, Richard Ofori‐Asenso, Juan Jesús Carrero, Helen Woodward, David Collins. Wheeler, Surendra Pentakota, Ewelina Palmer
article en
2 citations

Abstract

Findings from this multinational qualitative study suggest that patients may experience symptoms and signs of disease prior to diagnosis; however, these are often nonspecific and may not be directly associated with CKD. Once diagnosed, the burden of CKD can have a diverse, negative impact on various aspects of patients' lives. This highlights the need for early identification of at-risk individuals, and the importance of early CKD diagnosis and management with guideline-directed therapies to either prevent further deterioration of CKD or slow its progression, thus reducing symptom burden and improving quality of life.

American Journal of NephrologyVol. 55(6)
AstraZeneca (United Kingdom) (GB), University of Akron (US), The University of Sydney (AU), Pontifícia Universidade Católica do Paraná (BR), Kawasaki Medical School (JP), Royal North Shore Hospital (AU), Kidney Research UK (GB), Karolinska Institutet (SE), AstraZeneca (France) (FR), AstraZeneca (Netherlands) (NL), AstraZeneca (Poland) (PL), AstraZeneca (Finland) (FI), AstraZeneca (Sweden) (SE), AstraZeneca (Spain) (ES), Zucker Hillside Hospital (US), University College London (GB)
Openalex Percentile: Top 27%
Dialysis and Renal Disease Management
0.68
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.